Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Pulmonary Eosinophilia

• AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
• A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
• A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
• A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
• A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
• A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
• A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
• XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
• Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
• Predictive Signature of Benralizumab Response
• Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
• Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
• PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
• Phase 4 Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Subjects Aged >=18 Years With Severe Eosinophilic Asthma Requiring Maintenance Oral Corticosteroids
• A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
• A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
• Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
• Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
• CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients
• Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
• Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma
• A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
• Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
• Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
• Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
• Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
• Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
• Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
• A Phase IIa Study of KHK4563
• Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
• Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
• A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
• A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
• A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
• The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia